Abstract library

26 results for "Osher".
#502 Bifunctional ShRNAimPDX-1 Therapy Prevents Hypoglycemic Death From Insulinoma in Mice
Introduction: PDX-1 is a novel molecular target for insulinoma. Bi-functional shRNAi platform has been developed that results in a more effective targeted gene knockdown.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr F Charles Brunicardi
Authors: Liu S, Wang Z, Shahi K, Rao D, ...
#511 Intrapancreatic Accessory Spleen (IPAS) Misdiagnosed as Nonfunctioning Pancreatic Neuroendocrine Tumor (PNET): A Case Report and Characterization of a Syndrome Based on Systematic Review of the Literature
Introduction: Management of pancreatic incidentalomas(PI) is challenging due to high risk of malignancy and limitations in prediction of their histology and biological behavior. IPAS is one of such lesions and is often misdiagnosed as a PNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Esther Osher
Keywords: IPAS
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan
#713 Non-Functioning Pancreatic Neuroendocrine Tumors (PNET): Association with Prediabetes/Diabetes
Introduction: Neuroendocrine tumors of pancreas (PNET) are classified as functional or nonfunctional (NF) based on presence or absence of clinical syndrome associated with hormone over secretion. NF-PNETs do, however, often produce low levels of inactive hormones (pancreatic polypeptide, calcitonin or neurotensin) which do not cause any symptoms.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Etyy Osher
Keywords: NF-PNET, DM/IFG
#1101 Malignant Insulinoma in a Patient with Diabetes: Response to Treatment and a Return to Insulin Injections
Introduction: A 64 year old male with a fourteen year history of diabetes had been treated with insulin for eight years. Over a four week period he noticed that his insulin requirements were reducing and he experienced episodes of symptomatic hypoglycaemia and upper abdominal pain. Following referral a CT scan was performed which revealed numerous liver metastases and a 8.4 by 5.2 cm mass replacing the pancreas. Liver biopsy diagnosed a neuroendocrine tumour with a MIB-1 index of up to 18%. The tumour was somatostatin receptor positive as evidenced by an octreotide scan.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr David Sherriff
Authors: Sherriff D, Drake B, ...
Keywords: insulinoma, diabetes, prrt
#1177 An Isolated Abnormal Chromogranin B Is Associated with Pancreato-Duodenal NETs and the Presence of Liver Metastases
Introduction: Chromogranin B (CgB) is a soluble secretory protein like chromogranin A (CgA) that has been reported to be elevated in patients with neuroendocrine tumours (NETs) but is not routinely assessed.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Ron Basuroy
#1332 NT-proBNP is Superior to ST2 and Galectin-3 Cardiac Markers in Identifying Carcinoid Heart Disease in Small Bowel NET Patients
Introduction: Carcinoid heart disease (CHD) develops in small bowel neuroendocrine tumour (sbNET) patients with carcinoid syndrome (CS). NT-proBNP (NTP) is suggested as the best current biomarker to screen and monitor for HF from CHD. A number of other markers, such as Galectin-3 (GAL3) and ST2 (or IL-1 R4), have been explored to diagnose and prognosticate in HF but have not been explored in NET patients with CS and CHD.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Ron Basuroy
#1586 Biomarkers for Carcinoid Heart Disease
Introduction: Carcinoid heart disease (CHD) develops in patients with carcinoid syndrome. Currently NT-proBNP (NTP) is suggested as the best current biomarker to screen for CHD and monitor heart failure. A number of other markers have been investigated for heart failure.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Dr Raj Srirajaskanthan
#1811 Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Alexandria T Phan
Keywords: Lanreotide, safety
#2866 Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Hong Hong Song
Authors: Song H, Kunz P, Franc B, Moradi F, ...